Clinical Research Directory

Inclusion Criteria: 1. To provide a signed and dated, written informed consent. 2. 80≥Age ≥ 18 years old 3. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory 4. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated. 5. Predicted life expectancy ≥ 12 weeks 6. EGFR-TKI resistance or intolerant to standard EGFR TKIs therapy. 7. No previous systemic chemotherapy for advanced or metastatic disease. 8. Adequate organ system function: 9. Patient must have measurable disease according to RECIST 1.1. 10. Patients with stable or pre-treated brain metastasis (BM) can be enrolled Exclusion Criteria: 1. Spinal cord compression or meningeal metastasis 2. A history of malignant tumors within 2 years. 3. With known resistant mutations that have approved target therapy 4. Recover from AEs caused by previous treatment 5. A history of stroke or intracranial hemorrhage within 6 months prior to initial dosing. 6. Any severe or poorly controlled systemic disease per investigator's judgment active infections, including but not limited to hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency (HIV)